UBS Reiterates a 'Buy' on Heartware Int'l (HTWR); Very Positive Outcome
Tweet
Share
E-mailGet Alerts HTWR Hot Sheet
Price: $57.98 --0%
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 22 | New: 45
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 22 | New: 45
Join SI Premium – FREE
UBS reiterates a 'Buy' on Heartware Int'l (NASDAQ: HTWR) price target raised from $95 to $110.
Analyst, Rajeev Jashnani, said, "Summary of panel votes: safety 8-3 in favor of HVAD; efficacy 11-0 in favor of HVAD; risk/benefit 9-2 in favor of HVAD. Votes were overwhelmingly positive. Panelists seemed comfortable w/ ischemic stroke & pump thrombosis, key concerns related to trial execution, primarily CEC issues (this is the group that adjudicates AE's; composition changed over course of trial & some procedures were called into question). Panel wanted to see safety from INTERMACS control group, but this concern seems misplaced given self-reporting w/ that database."
Jashnani noted that approval may not be right around the corner (may be up to several months), but FDA sintering data should be straightforward and UBS is hopeful for a quick approval.
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $69.27 yesterday.
Analyst, Rajeev Jashnani, said, "Summary of panel votes: safety 8-3 in favor of HVAD; efficacy 11-0 in favor of HVAD; risk/benefit 9-2 in favor of HVAD. Votes were overwhelmingly positive. Panelists seemed comfortable w/ ischemic stroke & pump thrombosis, key concerns related to trial execution, primarily CEC issues (this is the group that adjudicates AE's; composition changed over course of trial & some procedures were called into question). Panel wanted to see safety from INTERMACS control group, but this concern seems misplaced given self-reporting w/ that database."
Jashnani noted that approval may not be right around the corner (may be up to several months), but FDA sintering data should be straightforward and UBS is hopeful for a quick approval.
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $69.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phoenix Education Partners (PXED) PT Lowered to $40 at Morgan Stanley
- Pan American Silver Corp (PAAS:CN) (PAAS) PT Raised to Cdn$95 at Scotiabank
- Industrial Alliance Insurance & Financial Services Inc. (IAG:CN) (IDLLF) PT Raised to Cdn$198.52 at Scotiabank
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
